Polymorphisms in DNA Repair and Apoptosis Pathway Genes and Clinical Outcomes of Patients with Non-small Cell Lung Cancer Treated with First-line Paclitaxel-cisplatin Chemotherapy
분야
의약학 > 내과학
저자
이신엽 , 강효경 , 최의영 , 최진은 , 전효성 , 신경민 , 유승수 , 이재희 , 차승익 , 김창호 , 박재용
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 174(총1페이지)
파일형식
0y909855.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    This study was conducted to analyze a comprehensive panel of single nucleotide polymorphisms (SNPs) in genes in DNA repair and apoptosis pathways to determine the relationship between polymorphisms and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with first line paclitaxel-cisplatin chemotherapy. Three hundred eighty two patients with NSCLC were enrolled. Seventy-four SNPs in 48 genes (42 SNPs in 27 DNA repair pathway genes and 32 SNPs in 21 apoptotic pathway genes) were genotyped and their associations with response to chemotherapy and overall survival (OS) were analyzed. Results: Among SNPs in DNA repair genes, BRCA1 rs799917 was significantly associated with both response to chemotherapy and OS. XRCC1 rs25487 exhibited significant association with response to chemotherapy and XPD/ERCC2 rs1052555 with OS. Four SNPs in apoptotic genes (TNFRSF1B rs1061624, BCL2 rs2279115, BIRC5 rs9904341, and CASP8 rs3769818) were significantly associated with OS, but not with response to chemotherapy. When the six SNPs which were associated with OS in individual analysis were combined, OS w decreased as the number of bad genotypes increased (Ptrend=2×10-6). Patients with 3, and 4-6 bad genotypes had a significantly worse OS compared with those carrying 0-2 bad genotypes (aHR=1.54, 95% CI=1.14-2.08, P=0.005; aHR=2.10, 95% CI=1.55-2.85, P=2×10-6, respectively). These findings suggest that the SNPs identified can be used as biomarkers predicting chemotherapy response and survival for NSCLC patients treated with first line paclitaxel-cisplatin.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.